Comparative safety and tolerability of angiotensin II receptor antagonists

Drug Safety

Volumn 21, Issue 1, 1999, Pages 23-33

  Mazzolai, Lucia ^a   Burnier, Michel ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II ANTAGONIST;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN II; ANTIHYPERTENSIVE AGENTS; DRUG INTERACTIONS; HUMANS; RECEPTORS, ANGIOTENSIN;

EID: 0032877186     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199921010-00003     Document Type: Review

References (84)

1. 1. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease: part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74
2. th report of the Joint National Committee on detection, evaluation and treatment of high blood pressure (JNC V). Arch Int Med 1993; 153: 154-83
3. 3. Timmermans PBMWM, Benfield P, Chiu AT, et al. Angiotensin II receptor and functional correlates. Am J Hypertens 1992; 5: 221S-35S
4. 4. Wexler RR, Carini DJ, Duncia JV, et al. Rationale for the chemical development of angiotensin II receptor antagonists. Am J Hypertens 1992; 5: 209s-20s
5. 5. Burnier M, Brunner HR. Angiotensin II receptor antagonists-antihypertensive agents. Exp Opin Invest Drugs 1997; 6: 489-500
6. 6. Wexler RR, Greenlee WJ, Irvin JD. Non-peptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. J Med Chem 1996; 39: 625-56
7. 7. Mallion JM, Goldberg AI. Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist in the treatment of hypertension. Blood Press 1996; 5 Suppl. 2: 82-6
8. 8. McClellan JK, Goa KL. Candersartan cilexetil: a review of its use in essential hypertensions. Drugs 1998; 56 (5): 847-69
9. 9. Markham A, Goa KL. Valsartan: a review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997; 54 (2): 299-311
10. 10. Gillis JC, Merkham A. Irbesartan: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997; 54 (6): 885-902
11. 11. McIntyre M, Coffe SE, Michalok RA, et al. Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension. Pharmacol Ther 1997; 74 (2): 181-94
12. 12. Waeber M. Clinical safety and tolerability of losartan. Clin Ther 1997; 19 (4): 604-16
13. 13. Haddad AM, Scholer SG. Possible losartan-induced rash. Am J Health Syst Pharm 1997; 54 (11): 1333-4
14. 14. Bosch X. Henoch-Schönlein purpura induced by losartan therapy. Arch Int Med 1998; 158: 191-2
15. 15. Viraben R, Lamant L, Brousset P. Losartan-associated atypical cutaneous lymphoid hyperplasia. Lancet 1997; 350: 1366
16. 16. Magro C, Crowson A. Drug-induced immune dysregulation as a cause of atypical cutaneous lymphoid infiltrates. Hum Pathol 1996; 27: 125-32
17. 17. Israíli ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med 1992; 117: 234-42
18. 18. Lacourcière Y, Lefebvre J, Nakhle G, et al. Association between cough and angiotensin converting enzyme inhibitory versus angiotensin II antagonists: the design of a prospective, controlled study. J Hypertens 1994; 12: 549-53
19. 19. Black HR, Graff A, Shute D, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, linopril. J Hum Hypertens 1997; 11: 483-9
20. 20. Belcher G, Hübner R, George M, et al. Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension. J Hum Hypertens 1998; 11: S85-S9
21. 21. Lacourcière Y, Brunner HR, Irwing R, et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994; 12: 1387-93
22. 22. Benz J, Oshrain C, Henry D, et al. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol 1997; 37: 101-7
23. 23. Nussberger J, Cugno M, Amstutz C, et al. Plasma bradykinin in angio-oedema. Lancet 1998; 351: 1693-7
24. 24. Vleeming W, van Amsterdam JG, Stricker BH, et al. ACE inhibitor-induced angioedema: incidence, prevention and management. Drug Saf 1998; 18 (3): 171-88
25. 25. Merck & Co., Inc. Losartan potassium prescribing information, West Point, PSA 19486, USA, 1995
26. 26. Acker CG, Greenberg A. Angioedema induced by the angiotensin II blocker losartan [letter]. N Engl J Med 1995; 333: 1572
27. 27. van Rijnsoever EW, Kwee-Zuiderwijk WJ, Feenstra J. Angioneurotic edema attributed to the use of losartan. Arch Intern Med 1998; 158 (18): 2063-5
28. 28. Griffin J. Drug-induced disorders of taste. Adverse Drug React Toxicol 1992; 11: 229-39
29. 29. Schlienger R, Saxer M, Haefli W. Reversible ageusia associated with losartan. Lancet 1996; 347: 471-2
30. 30. Heeringa M, van Puijenbroek EP. Reversible dysgeusia attributed to losartan. Ann Int Med 1998; 129 (1): 72
31. 31. Ahmad S. Losartan and severe migraine. JAMA 1995; 274 (16): 1266-7
32. 32. Ahmad S. Losartan and reversible psychosis. Cardiology 1996; 87: 569-70
33. 33. Shand B, Gilchrist N, Nicholls M, et al. Effect of losartan on haematology and haemorheology in elderly patients with essential hypertension: a pilot study. J Hum Hypertens 1995; 9: 233-5
34. 34. Schwarzbeck A, Wittenmeier U. Hällfritzsch anaemia in dialysis patients as a side-effect of sartanes [letter]. Lancet 1998; 325: 286
35. 35. Julian BA, Brantley Jr RR, Barker CV, et al. Losartan, an angiotensin II type I receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. J Am Soc Nephrol 1998; 9 (6): 1104-8
36. 36. Schwarzbeck A, Wittenmeier KW, Hallfritzsch U. Anaemia in dialysis patients as a side-effect of sartanes Lancet 1998; 352 (9124): 286
37. 37. Navarro JF, Garcia J, Macia M, et al. Effects of losartan on the treatment of posttransplant erythrocytosis. Clin Nephrol 1998; 49 (6): 370-2
38. 38. Ducloux D, Fournier V, Bresson-Vautrin C, et al. Long-term follow-up of renal transplant recipients treated with losartan for post-transplant erythrosis. Transpl Int 1998; 11 (4): 312-5
39. 39. Hortal L, Fernandez A, Vega N, et al. Losartan versus ramipril in the treatment of postrenal transplant erythrocytosis. Transplant Proc 1998; 30 (5): 2127-8
40. 40. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 793-5
41. 41 Nakashima M, Uematsu T, Kosuge K, et al. Pilot study of the uricosuric effect of DuP 753, a new angiotensin II receptor antagonist, in healthy subjects. Eur Clin Pharmacol 1992; 42: 333-5
42. 42. Burnier M, Rutschmann B, Nussberger J, et al. Salt-dependent renal effects of angiotensin II antagonist in healthy subjects. Hypertension 1993; 22: 339-47
43. 43. Burnier M, Roch-Ramel F, Brunner HR. Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int 1996; 49: 1787-90
44. 44. Sweet CS, Bradstreet DC, Berman RS, et al. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens 1994; 7: 1035-40
45. 45. Soffer BA, Wright JT, Pratt H, et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995; 26: 112-7
46. 46. Shahinfar S, Simpson C, Carides A, et al. Safety of losartan in hypertensive patients with asymptomatic hyperuricemia [abstract]. J Am Soc Nephrol 1997; 8: 322a
47. 47. Minghelli G, Seydoux C, Goy J, et al. Uricosuric effect of losartan in cyclosporine-treated heart transplant recipients. Transplantation 1998; 66 (2): 268-71
48. 48. Burnier M, Hagman M, Nussberger J, et al. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 1995; 25: 602-9
49. 49. Ilson BE, Martin DE, Boike SC, et al. The effects of eprosartan, an angiotensin II AT1 receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension. J Clin Pharmacol 1998; 38 (5): 437-41
50. 50. Bauer J, Reams GP. The angiotensin II type I receptor antagonists. A new class of antihypertensive drugs. Arch Int Med 1995; 155: 1361-8
51. 51. De Zeeuw D, Gansevoort RT, Dullaart RP, et al. Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome. J Hypertens 1995; 13: S53-S8
52. 52. Moan A, Hoieggen A, Seljeflot I, et al. The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity. J Hypertens 1996; 14 (9): 1093-7
53. 53. Laakso M, Karjalainen L, Lempiäinen-Kuosa P. Effects of losartan on insulin sensitivity in hypertensive subjects. Hypertension 1996; 28: 392-6
54. 54. Lankisch PG, Droge M, Gottesleben F. Drug-induced pancreatitis: incidence and severity. Gut 1995; 37: 565-7
55. 55. Bosch X. Losartan-induced acute pancreatitis. Ann Intern Med 1997; 127: 1043-4
56. 56. Birck R, Keim V, Fiedler F, et al. Pancreatitis after losartan. Lancet 1998; 351 (9110): 1178
57. 57. Sever P, Candesartan cilexetil: a new, long-acting, effective angiotensin II type I receptor blocker. J Hum Hypertens 1997; 11: S91-S5
58. 58. McInnes GT, O'Kane KPJ, Jonker J, et al. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. J Hum Hypertens 1997; 11 (Suppl. 2): S75-S80
59. 59. Christen Y, Waeber B, Nussberger J, et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers: inhibition of pressor response to exogenous angiotensin I and II. Circulation 1991; 83: 1333-42
60. 60. Mallion JM, Bradstreet DC, Makris L, et al. Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension. J Hypertens 1995; 13 (Suppl. 1): 35-41
61. 61. Dahlöf B, Keller S, Makris L, et al. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens 1995; 8: 578-83
62. 62. Burrell LM, Johnston CI. Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease. Drug Ther 1997; 10: 421-34
63. 63. Gillis JC, Markham A. Irbesartan: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997; 54 (6): 885-902
64. 64. Chioléro A, Burnier M. Pharmacology of valsartan, an angiotensin II receptor antagonist. Exp Opin Invest Drugs 1998; 7 (11): 1915-25
65. 65. Sica DA, Lo MW, Shaw WC, et al. The pharmacokinetics of losartan in renal insufficiency. J Hypertens 1995; 13: S49-S52
66. 66. Sica DA, Marino MR, Hammett JL, et al. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis. Clin Pharm Ther 1997; 62 (6): 610-8
67. 67. DeZeeuw D, Remuzzi G, Kirch W. Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment. J Hum Hypertens 1997; 11 (Suppl. 2), S37-42
68. 68. Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346: 1403-7
69. 69. Toto R, Shultz P, Raij L, et al. Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Hypertension 1998; 31: 684-91
70. 70. Gansevoort RT, DeZeeuw D, deJong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994; 45: 861-7
71. 1 antagonist irbesartan vs enalapril in hypertensive patients. J Hypertens 1998; 16: 385-93
72. 72. Mimran A, Ribstein J, DuCailar G. Comparison of the acute renal effect of losartan and captoptil in atheromatous renovascular disease. Am J Hypertens 1998; 11: 47A
73. 73. Saine D, Ahrens E. Renal impairment associated with losartan. Ann Intern Med 1996; 124: 775
74. 74. Marino MR, Langenbacher KM, Raymond RH, et al. Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis. J Clin Pharmacol 1998; 38 (4): 347-56
75. 75. Brookman LJ, Rolan PE, Benjamin IS, et al. Pharmacokinetics of valsartan in patients with liver disease. Clin Pharm Ther 1997; 62 (3): 272-8
76. 76. Gottlieb SS, Dickstein K, Fleck E, et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993; 8: 1602-9
77. 77. Dickstein K, Chang P, Willenheimer R, et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe heart failure. J Am Coll Cardiol 1995; 26: 438-45
78. 78. Crozier I, Ikram H, Awan N, et al. Circulation 1995; 91: 691-7
79. 79. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE). Lancet 1997; 349: 747-52
80. 80. Kreft-Joris C, Plouin PF, Tchobroutsky C. Angiotensin converting enzyme inhibitors during pregnancy. J Hypertens 1987; 5 (Suppl. 5): 553-4
81. 81. Kong AN, Tomasko L, Waldman SA, et al. Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1995; 35: 1008-15
82. 82. Fricker A, Nussberger J, Meilenbrock S, et al. Effect of indomethacin on the renal response to angiotensin II receptor blockade in healthy subjects. Kidney Int 1998; 54: 2089-97
83. 83. Timmermans PBMWM, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45 (2): 205-51
84. 2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995; 95: 651-7